Interestingly, we have previously shown that CML LT-HSCs with higher levels of MPL expression have increased leukemogenic capacity and reduced TKI sensitivity (35). The gene discussed is MPL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.